BioPharma Fueled With $100M, Autobahn Therapeutics Gears Up for Depression Drug Clinical Trials By Frank Vinluan
BioPharma, Pharma CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug By Frank Vinluan
BioPharma, Pharma Lycia Therapeutics Lands $106M for Protein Degraders That Treat Autoimmune & Inflammatory Diseases By Frank Vinluan
BioPharma, Pharma Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations By Frank Vinluan
BioPharma, Pharma Travere Therapeutics Drug for Rare Kidney Disease Falls Short in Pivotal Test By Frank Vinluan
BioPharma, Pharma Sanofi Finds Way to Maze Therapeutics to Get Its Next Pompe Disease Drug By Frank Vinluan
BioPharma, Pharma Alentis Therapeutics Lands $105M for Clinical Trials in Fibrosis and Cancer By Frank Vinluan
BioPharma, Pharma Chinook Therapeutics Pauses Kidney Disease Drug Trial Following Adverse Event Report By Frank Vinluan
BioPharma, Pharma Structure Therapeutics’ IPO Raises $161M for Pills to Rival Blockbuster Biologics By Frank Vinluan
MedCitizens Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy By Stephanie Baum
BioPharma, Pharma Modest activity, tolerability issues sink lead Harpoon cancer drug prospect By Frank Vinluan
MedCitizens CEO of digital therapeutics business Freespira talks about its approach to anxiety disorders By MedCity News
BioPharma, Pharma Seres Therapeutics microbiome drug flunks Phase 2 test in ulcerative colitis By Frank Vinluan
